The role of biological response modifiers in metastatic renal cell carcinoma
Muss, H.B.
Seminars in Oncology 15(5 Suppl 5: 30-34
1988
ISSN/ISBN: 0093-7754 PMID: 2461595 Document Number: 324772
Document emailed within 1 workday
Related Documents
Quesada, J.R. 1988: Biologic response modifiers in the therapy of metastatic renal cell carcinoma Seminars in Oncology 15(4): 396-407Ackermann, R. 1988: Biological response modifiers in renal cancer Progress in Clinical and Biological Research 269: 313-328
Lee, D.S.; White, D.E.; Hurst, R.; Rosenberg, S.A.; Yang, J.C. 1998: Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy Cancer Journal From Scientific American 4(2): 86-93
Dutcher, J.P. 2011: High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard Oncology 25(5): 427-428
Ishihara, K. 1989: On the behalf of the Japanese Society of Biological Response Modifiers Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(4 Pt 2-1): 906-911
Coşkun, F.; Cetinkaya, M.; Cengiz, O.; Adsan, O.; Kulaçoğlu, S.; Eroğlu, A. 1995: Metastatic carcinoma of the gallbladder due to renal cell carcinoma in the ectopic kidney Acta Chirurgica Belgica 95(1): 56-58
Sarma, D.P.; Wang, J.F.; McAllister, M.V.; Wang, B.; Shehan, J.M. 2008: Possible implantation carcinoma of the scalp following craniotomy for metastatic renal cell carcinoma Dermatology Online Journal 14(6): 20
Scheinberg, M.A. 1988: Clinical trials with biological response modifiers in rheumatic diseases Journal of Rheumatology 15(7): 1056-1057
Kirkpatrick, C.H. 1989: Biological response modifiers. Interferons, interleukins, and transfer factor Annals of Allergy 62(3): 170-176
Okawa, T.; Goto, M.; Kita, M. 1987: Radiotherapy combined with BRM (biological response modifiers) in the treatment of cancer Gan no Rinsho. Japan Journal of Cancer Clinics 33(10): 1253-1256
Zlotta, A.R.; Schulman, C.C. 2000: Biological response modifiers for the treatment of superficial bladder tumors European Urology 37(Suppl): 10-15
Saito, A. 2001: A putative immunotherapy with biological response modifiers (BRM) against intractable pulmonary tuberculosis Kekkaku: 76(12): 741-747
Irwin, M.M. 1987: Patients receiving biological response modifiers: overview of nursing care Oncology Nursing Forum 14(6 Suppl): 32-37
Koga, H.; Miyazaki, Y.; Kohno, S.; Hara, K. 1994: A drug delivery system and biological response modifiers for the treatment of mycobacterial infection Kekkaku: 69(2): 113-118
Iurin, A.G.; Koval'skiĭ, G.B. 2009: Analysis of survival rates in patients and prognostic models in non-metastatic clear-cell renal cell carcinoma Arkhiv Patologii 71(6): 15-20
He, C.; Qin, C.; Xu, T.; Yuan, Y.; Liu, Z.; Sheng, Z.; Hu, F.; Dun, Y.; Wang, X. 2015: Expression of glycoprotein non-metastatic melanoma protein B in clear-cell renal cell carcinoma and clinical implication thereof Zhonghua Yi Xue Za Zhi 95(30): 2455-2458
Talmadge, J.E.; Herberman, R.B. 1986: The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers Cancer Treatment Reports 70(1): 171-182
Bergmann, L. 1989: Malignant melanoma--prognosis and actual treatment strategies with chemotherapy and biological response modifiers European Journal of Cancer and Clinical Oncology 25(Suppl 3): S31-S36
Lukesová, S.; Vroblová, V.; Hlávková, D.; Kopecký, O.; Vokurková, D.; Morávek, P.; Safránek, H.; Soucek, P. 2008: Monitoring of anti-tumour cell-mediated response in patients with renal cell carcinoma, disturbance of T cell proliferation Vnitrni Lekarstvi 54(2): 139-145
Joshi, D.P.; Shah, R.B.; Montie, J.E.; Lee, C.T. 2002: Isolated recurrent renal cell carcinoma metastatic to the bladder Journal of the National Medical Association 94(10): 912-914